Description: Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company's lead drug candidate is HXP124, which is in a phase IIb clinical trial for the treatment of fungal toenail infections. It operates in the topical antifungal sector of the pharmaceutical product development industry worldwide. The company was founded in 1997 and is headquartered in Melbourne, Australia.
Home Page: www.hexima.com.au
HXL Technical Analysis
Corporate One
Preston,
VIC
3072
Australia
Phone:
61 3 9479 1210
Officers
| Name | Title |
|---|---|
| Dr. Nicole van der Weerden B.Sc., BSc (Hons), MBA (MBS), Ph.D. | Acting CEO, COO & Exec. Director |
| Ms. Helen Molloy | Financial Controller |
| Prof. Marilyn A. Anderson A.O., AO, B.Sc., BSc (Hons), FAA, FAICD, FT | Chief Science Officer |
| Dr. Nancy Sacco | Chief Devel. Officer |
| Ms. Leanne Ralph | Company Sec. |
| Dr. Neil Forrester | VP of Bus. Devel. |
| Prof. Adrienne Elizabeth Clarke | Science Advisor |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8414 |
| Price-to-Sales TTM: | 0.6612 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |